Pulmonary Arterial Hypertension

2010 European Medicines Agency. Guidelines on Pharmacovigilance for Medicinal Products for Human Use. Available at: http://ec.europa.eu/health/documents/eudralex/vol-9/index_en.htm. Accessed November 6, 2013. Dreyer, 2010, GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness, Am J Manag Care, 16, 467 Suissa, 2008, Immortal time bias in pharmacoepidemiology, Am J Epidemiol, 167, 492, 10.1093/aje/kwm324 Rubin, 1996, Multiple imputation after 18+ years (with discussion), J Am Stat Assoc, 91, 473, 10.1080/01621459.1996.10476908 Lee, 2012, Predicting survival in pulmonary arterial hypertension in the UK, Eur Respir J, 40, 604, 10.1183/09031936.00196611 Miller, 2012, Survivor bias and risk assessment, Eur Respir J, 40, 530, 10.1183/09031936.00094112 McGoon, 2008, Design of the REVEAL Registry for US Patients with Pulmonary Arterial Hypertension, Mayo Clin Proc, 83, 923, 10.1016/S0025-6196(11)60769-6 Humbert, 2010, Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era, Circulation, 122, 156, 10.1161/CIRCULATIONAHA.109.911818 Benza, 2012, An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry, Chest, 142, 448, 10.1378/chest.11-1460 McGoon, 2012, REVEAL: a contemporary US pulmonary arterial hypertension registry, Eur Respir Rev, 21, 8, 10.1183/09059180.00008211 Frost, 2013, Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures of 16-18 mmHg: insights from REVEAL, Chest, 143, 185, 10.1378/chest.11-1387 2008, Guidelines for good pharmacoepidemiology practices (GPP), Pharmacoepidemiol Drug Saf, 17, 200, 10.1002/pds.1471 von Elm, 2007, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, PLoS Med, 4, e296, 10.1371/journal.pmed.0040296 Levine, 2008, Registries that show efficacy: good, but not good enough, J Clin Oncol, 26, 5316, 10.1200/JCO.2008.18.3996 Vandenbroucke, 2008, Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects, JAMA, 300, 2417, 10.1001/jama.2008.723 D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension: results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Rich, 1987, Primary pulmonary hypertension: a national prospective study, Ann Intern Med, 107, 216, 10.7326/0003-4819-107-2-216 Thenappan, 2010, Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation, Eur Respir J, 35, 1079, 10.1183/09031936.00072709 Peacock, 2007, An epidemiological study of pulmonary arterial hypertension, Eur Respir J, 30, 104, 10.1183/09031936.00092306 Humbert, 2010, Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension, Eur Respir J, 36, 549, 10.1183/09031936.00057010 Humbert, 2006, Pulmonary arterial hypertension in France: results from a national registry, Am J Respir Crit Care Med, 173, 1023, 10.1164/rccm.200510-1668OC Jing, 2007, Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension, Chest, 132, 373, 10.1378/chest.06-2913 Badesch, 2010, Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry, Chest, 137, 376, 10.1378/chest.09-1140 Barst, 2012, Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management, Circulation, 125, 113, 10.1161/CIRCULATIONAHA.111.026591 Benza, 2010, Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry, Transplantation, 90, 298, 10.1097/TP.0b013e3181e49b83 Benza, 2010, Predicting survival in pulmonary arterial hypertension. Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL), Circulation, 122, 164, 10.1161/CIRCULATIONAHA.109.898122 Brown, 2011, Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry, Chest, 140, 19, 10.1378/chest.10-1166 Chung, 2010, Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype, Chest, 138, 1383, 10.1378/chest.10-0260 Farber, 2011, REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension, Congest Heart Fail, 17, 56, 10.1111/j.1751-7133.2010.00202.x Frost, 2011, The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries, Chest, 139, 128, 10.1378/chest.10-0075 Krowka, 2012, Portopulmonary hypertension: a report from the US-based REVEAL Registry, Chest, 141, 906, 10.1378/chest.11-0160 Shapiro, 2012, Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management, Chest, 141, 363, 10.1378/chest.10-3114 Escribano-Subias, 2012, Survival in pulmonary hypertension in Spain: insights from the Spanish registry, Eur Respir J, 40, 596, 10.1183/09031936.00101211 Ling, 2012, Changing demographics, epidemiology and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland, Am J Respir Crit Care Med, 186, 790, 10.1164/rccm.201203-0383OC Jiang, 2012, Idiopathic pulmonary arterial hypertension and its prognosis in the modern management era in developed and developing countries, 85 Zhang, 2011, Survival of Chinese patients with pulmonary arterial hypertension in the modern management era, Chest, 140, 301, 10.1378/chest.10-2327 Kane, 2011, Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension, Chest, 139, 1285, 10.1378/chest.10-1293 Hoeper, 2013, Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry, Int J Cardiol, 168, 871, 10.1016/j.ijcard.2012.10.026 Benza, 2012, The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension, Chest, 141, 354, 10.1378/chest.11-0676 Delgado-Rodriguez, 2004, Bias, J Epidemiol Commun Health, 58, 635, 10.1136/jech.2003.008466 Campbell, 2007, A national survey of physician-industry relationships, N Engl J Med, 356, 1742, 10.1056/NEJMsa064508 Bossone, 2005, Pulmonary arterial hypertension–the key role of echocardiography, Chest, 127, 1836, 10.1378/chest.127.5.1836 Cogswell, 2012, Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival, J Heart Lung Transplant, 31, 1165, 10.1016/j.healun.2012.08.009 Cogswell, 2013, Performance of the REVEAL model in WHO Group 2 to 5 pulmonary hypertension: application beyond pulmonary arterial hypertension, J Heart Lung Transplant, 32, 293, 10.1016/j.healun.2012.11.012 McGoon, 2012, External validation of the French predictive model to estimate PAH survival: a REVEAL® analysis, Eur Respir J, 40, 41S Sitbon, 2012, External validation of the REVEAL risk score calculator for PAH survival: a French pulmonary hypertension network analysis (abstr), Eur Respir J, 40, 41S Hurdman, 2012, ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre, Eur Respir J, 39, 945, 10.1183/09031936.00078411 Hurdman, 2012, Pulmonary hypertension in COPD: results from the ASPIRE registry, Eur Respir J, 41, 292 Pepke-Zaba, 2011, Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry, Circulation, 124, 1973, 10.1161/CIRCULATIONAHA.110.015008 Gomberg-Maitland, 2010, A global pulmonary arterial hypertension registry: is it needed? Is it feasible? Pulmonary vascular disease: the global perspective, Chest, 137, 95S, 10.1378/chest.09-3008 Beghetti, 2013, Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice, Eur Respir J, 42, 689, 10.1183/09031936.00140112 Berger, 2012, Clinical features of paediatric pulmonary hypertension: a registry study, Lancet, 379, 537, 10.1016/S0140-6736(11)61621-8 Hansmann, 2013, Registries for paediatric pulmonary hypertension, Eur Respir J, 42, 580, 10.1183/09031936.00065713 Humbert, 2007, Results of European post-marketing surveillance of bosentan in pulmonary hypertension, Eur Respir J, 30, 228, 10.1183/09031936.00138706